Valuation: Clarity Pharmaceuticals Ltd

Market Cap 685M 457M 416M 385M 349M 654M 42.69B 4.66B 1.85B 23.07B 1.71B 1.68B 73.07B P/E 2027 *
-6x
P/E 2028 * -6.14x
Enterprise Value 616M 411M 375M 347M 314M 589M 38.43B 4.19B 1.66B 20.76B 1.54B 1.51B 65.78B EV / Sales 2027 *
224x
EV / Sales 2028 * 24.3x
Free-Float
78.88%
Yield 2027 *
-
Yield 2028 * -
1 day-3.54%
1 week-2.48%
Current month+12.74%
3 months-32.44%
6 months-29.76%
Current year-47.63%
1 week 1.74
Extreme 1.745
1.97
1 month 1.34
Extreme 1.34
2.35
Current year 1.34
Extreme 1.34
4.26
1 year 1.34
Extreme 1.34
4.26
3 years 1.26
Extreme 1.255
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
Manager TitleAgeSince
Chief Executive Officer - 11/10/2024
Chief Executive Officer - 01/01/2010
Director of Finance/CFO - 04/04/2022
Director TitleAgeSince
Chairman - 01/11/2013
Director/Board Member - 01/10/2010
Director/Board Member 72 29/03/2016
Date Insider Type Main position Quantity % Market Cap. Importance
22/4/26 Sell

Chief Executive Officer

360,896 0.0969%
28/11/25 Free

Chief Operating Officer

199,909 0.0537%
28/11/25 Free

Chief Operating Officer

287,530 0.0773%
Change 5-day change 1-year change 3-year change Capi.($)
-3.54%-2.48%-52.55%+33.08% 457M
+0.19%-3.96%+54.92%+69.15% 65.42B
-0.56%-2.85%+6.28%+89.35% 58.91B
-1.53%-1.29%+24.04%+84.04% 55.24B
-0.97%-3.91%+12.98%+113.88% 45.66B
-2.83%-7.58%+15.21%+22.34% 41.29B
+3.61%+2.63%+21.96%+46.39% 36.82B
-0.24%-9.59%+126.05%+647.44% 34.48B
+0.09%+1.51%+78.85%+57.66% 32.5B
+20.58%+22.35%-29.03%+482.03% 31.69B
Average +1.48%-1.40%+25.87%+164.54% 40B
Weighted average by Cap. +1.27%-0.99%+33.01%+153.43%

Financials

2027 *2028 *
Net sales 2.75M 1.84M 1.67M 1.55M 1.4M 2.63M 171M 18.72M 7.42M 92.65M 6.89M 6.74M 293M 24.23M 16.18M 14.74M 13.64M 12.34M 23.15M 1.51B 165M 65.42M 816M 60.69M 59.42M 2.59B
Net income -116M -77.68M -70.78M -65.52M -59.27M -111M -7.26B -792M -314M -3.92B -291M -285M -12.42B -118M -78.66M -71.67M -66.34M -60.01M -113M -7.35B -802M -318M -3.97B -295M -289M -12.57B
Net Debt -68.3M -45.6M -41.54M -38.46M -34.79M -65.26M -4.26B -465M -184M -2.3B -171M -167M -7.29B -95.9M -64.02M -58.33M -54M -48.84M -91.63M -5.98B -653M -259M -3.23B -240M -235M -10.24B
Projected Income Statement - Annual - Clarity Pharmaceuticals Ltd
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Employees
100
Date Price Change Volume
20/11/26 $1.770 -3.54% 4,919,786
19/11/26 $1.835 +0.27% 2,469,804
18/11/26 $1.830 -3.17% 1,984,874
17/11/26 $1.890 +3.56% 3,799,444
16/11/26 $1.825 +0.55% 3,707,100
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Clarity Pharmaceuticals Ltd
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.835AUD
Average target price
7.076AUD
Spread / Average Target
+285.61%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Clarity Pharmaceuticals Ltd